Cerenome (PSTV) Other Accumulated Expenses (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Other Accumulated Expenses of $146000.0 for Q1 2026, down 8.18% quarter-over-quarter from $159000.0 in Q4 2025.
Cerenome (PSTV) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Other Accumulated Expenses for 13 consecutive years, with $146000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $146000.0; the TTM figure through Mar 2026 stood at $146000.0 (changed N/A YoY), while the FY2025 annual figure was $159000.0, changed N/A from the prior year.
- Other Accumulated Expenses fell to $146000.0 in Q1 2026 per PSTV's latest filing, from $159000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $159000.0 in Q4 2025 and bottomed at $146000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146,000.00 |
| Dec 31, 2025 | 159,000.00 |
| Dec 31, 2021 | 122,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Dec 31, 2019 | 791,000.00 |
| Dec 31, 2018 | 201,000.00 |
| Dec 31, 2017 | 225,000.00 |
| Dec 31, 2016 | 1.75 Mn |
| Dec 31, 2015 | 2.02 Mn |
| Dec 31, 2014 | 2.01 Mn |
| Dec 31, 2013 | 2.17 Mn |
| Dec 31, 2012 | 2.07 Mn |
| Dec 31, 2011 | 1.57 Mn |